- Home
- CKPT
as 07-08-2024 4:00pm EST
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 80.3M | IPO Year: | 2017 |
| Target Price: | $22.60 | AVG Volume (30 days): | 376.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.30 - $3.62 | Next Earning Date: | 08-12-2024 |
| Revenue: | $68,000 | Revenue Growth: | -61.14% |
| Revenue Growth (this year): | -53.95% | Revenue Growth (next year): | 102695.70% |
Stock Insider Trading Activity of Checkpoint Therapeutics Inc. (CKPT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| GRAY WILLIAM GARRETT | CKPT | Chief Financial Officer | Feb 28 '24 | Sell | $2.07 | 2,035 | $4,212.45 | 145,224 | SEC Form 4 |
| Oliviero James F III | CKPT | CEO, President and Director | Feb 28 '24 | Sell | $2.06 | 5,894 | $12,141.64 | 350,836 | SEC Form 4 |
| GRAY WILLIAM GARRETT | CKPT | Chief Financial Officer | Feb 1 '24 | Sell | $1.95 | 4,115 | $8,024.25 | 147,259 | SEC Form 4 |
| Oliviero James F III | CKPT | CEO, President and Director | Feb 1 '24 | Sell | $2.01 | 11,900 | $23,919.00 | 369,680 | SEC Form 4 |
Latest Checkpoint Therapeutics Inc. News
CKPT Breaking Stock News: Dive into CKPT Ticker-Specific Updates for Smart Investing
MT Newswires
6 days ago
Checkpoint Therapeutics Resubmits Biologics License Application for Cosibelimab, Launches $12 Million Direct Share Offering
GlobeNewswire
6 days ago
Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
GlobeNewswire
6 days ago
Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab
MT Newswires
14 days ago
Checkpoint Therapeutics Plans to Resubmit Application for Cancer Treatment Candidate
GlobeNewswire
14 days ago
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission
The Telegraph
a month ago
Italian energy company targets Britain for fleet of 20 mini-nukes
Simply Wall St.
a month ago
It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend
Simply Wall St.
a month ago
Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?
Share on Social Networks:
Disclaimer
The information presented on this page, "CKPT Checkpoint Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.